Immunic Inc (IMUX)
$1.27
+0.06
(+4.96%)▲
Insights on Immunic Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 72.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 336.6%
Performance
- $1.20$1.32$1.27
5.51%
Downside
Day's Volatility :9.09%
Upside
3.79%
- $0.95$3.11$1.27
25.58%
Downside
52 Weeks Volatility :69.61%
Upside
59.16%
Returns
| Period | Immunic Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 1.68% | -0.7% | 0.0% |
6 Months | 1.68% | 6.6% | 0.0% |
1 Year | -25.31% | 3.7% | -1.5% |
3 Years | -91.0% | 14.0% | -21.8% |
Highlights
Market Capitalization | 115.1M |
Book Value | $0.64 |
Earnings Per Share (EPS) | -2.11 |
Wall Street Target Price | 11.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -68.13% |
Return On Equity TTM | -131.28% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -99.1M |
Diluted Eps TTM | -2.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.99 |
EPS Estimate Next Year | -0.92 |
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Next Quarter | -0.45 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 805.51%
Technicals Summary
Sell
Neutral
Buy
Immunic Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Immunic Inc | -7.63% | 1.68% | -25.31% | -91.0% | -92.57% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Immunic Inc | NA | NA | NA | -0.99 | -1.31 | -0.68 | NA | 0.64 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Immunic Inc | Buy | $115.1M | -92.57% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
RTW INVESTMENTS, LLC
4.82%Gratus Capital LLC
2.16%Omega Fund Management LLC
1.99%Vanguard Group Inc
1.88%Bvf Inc
1.28%UBS O'Connor LLC
0.67%
Corporate Announcements
Immunic Inc Earnings
Immunic Inc’s price-to-earnings ratio stands at None
Read More
Company Information
immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu
Organization | Immunic Inc |
Employees | 77 |
CEO | Dr. Duane D. Nash J.D., M.B.A., M.D. |
Industry | Pharmaceuticals: Major |
